Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Targeting Vulnerability in SMARCA4-Mutant Lung and Ovarian Cancers
FY 2022-23
Summary
The SMARCA4 gene encodes the protein SMARCA4 (BRG1) which plays an important role in the epigenetic regulation of gene expression. As such, a functional SMARCA4 gene is crucial for the maintenance of proper protein production and normal cellular processes within a cell. The SMARCA4 gene is often inactivated by mutations or other mechanisms in different cancer tumours, resulting in the loss of BRG1 expression in these tumours. In fact, SMARCA4 mutations have been found in about 10% of non-small cell lung cancers (NSCLCs) and in almost 100% of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a rare and often lethal cancer for young women. These cancers lack effective treatment options. Recently, our group has uncovered that SMARCA4 loss is selectively sensitive to CDK4/6 inhibitors (a type of drug that has mainly been used in breast cancer treatments). This study has since resulted in an ongoing clinical study (NCT03297606). However, as drug resistance is a common occurrence in cancer therapies, it is crucial to find additional treatment strategies to target cancers with SMARCA4 loss. The goal of this project to investigate another gene candidate HSD17B10 that has been identified from our previous studies which may serve as additional potential drug targets in SMARCA4-mutant cancers. We will also investigate the molecular mechanism underlying the dependency of HSD17B10 in these cancers. The outcome of this study will potentially broaden the treatment options available for SMARCA4-mutant NSCLC and SCCOHT.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486021
Name
Liao Minyan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting Vulnerability in SMARCA4-Mutant Lung and Ovarian Cancers
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Therapeutic Target
Abstract
The SMARCA4 gene encodes the protein SMARCA4 (BRG1) which plays an important role in the epigenetic regulation of gene expression. As such, a functional SMARCA4 gene is crucial for the maintenance of proper protein production and normal cellular processes within a cell. The SMARCA4 gene is often inactivated by mutations or other mechanisms in different cancer tumours, resulting in the loss of BRG1 expression in these tumours. In fact, SMARCA4 mutations have been found in about 10% of non-small cell lung cancers (NSCLCs) and in almost 100% of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a rare and often lethal cancer for young women. These cancers lack effective treatment options. Recently, our group has uncovered that SMARCA4 loss is selectively sensitive to CDK4/6 inhibitors (a type of drug that has mainly been used in breast cancer treatments). This study has since resulted in an ongoing clinical study (NCT03297606). However, as drug resistance is a common occurrence in cancer therapies, it is crucial to find additional treatment strategies to target cancers with SMARCA4 loss. The goal of this project to investigate another gene candidate HSD17B10 that has been identified from our previous studies which may serve as additional potential drug targets in SMARCA4-mutant cancers. We will also investigate the molecular mechanism underlying the dependency of HSD17B10 in these cancers. The outcome of this study will potentially broaden the treatment options available for SMARCA4-mutant NSCLC and SCCOHT.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Liao, Minyan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~